Study: Breakthrough med devices slower to market than blockbuster drugs

By Fink Densford

Medical device companies producing pioneering medical technology have a much longer, more expensive road to travel to achieve FDA approval than those developing new drugs, according to a new study out of the Harvard Business School.

Lead investigator Ariel Stern examined 30 years of FDA data, between 1977 and 2007, comparing processing time for all new drugs and high-risk medical devices cleared by the federal watchdog.

Advertisement

Stern found that while new drugs are generally the fastest to win FDA approval, with 1st entrants reaching approval 1-2% faster than follow-on drugs, new medical devices on average take a whopping 34% longer to get approved.

The longer approval process results in an average delay of 7.2 months, Stern said. The cost associated with the extra delay can be prohibitive as well, with a conservative estimate at $6.7 million. This comes on top of the estimated average of $94 million to bring a new high-risk device to market.

READ MORE HERE

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement